|
Market Closed -
Toronto S.E.
00:59:59 05/11/2026 +04
|
5-day change | 1st Jan Change | ||
| 0.0150 CAD | 0.00% |
|
0.00% | -40.00% |
| Market Cap | 918K 644K 584K 540K 487K 60.76M 951K 6.49M 2.57M 32.46M 2.42M 2.37M 103M | P/E 2024 |
-40.5x | P/E 2025 | -5.33x |
|---|---|---|---|---|---|
| Enterprise Value | 1.92M 1.35M 1.22M 1.13M 1.02M 127M 1.99M 13.55M 5.37M 67.77M 5.05M 4.94M 215M | EV / Sales 2024 |
929,496,174x | EV / Sales 2025 | - |
| Free-Float |
53.08% | Yield 2024 * |
-
| Yield 2025 | - |
Toronto S.E.CAD
| Markets | Quality | ||
|---|---|---|---|
Toronto S.E.
| GENX | Delayed | |
| GENPF | Delayed |
| 1 month | -25.00% | ||
| 6 months | -25.00% | ||
| Current year | -40.00% |
| 1 month | 0.02 | 0.02 | |
| Current year | 0.02 | 0.02 | |
| 1 year | 0.02 | 0.02 | |
| 3 years | 0.02 | 0.09 | |
| 5 years | 0.02 | 0.19 | |
| 10 years | 0.01 | 0.3 |
| Manager | Title | Age | Since |
|---|---|---|---|
Sina Pirooz
CEO | Chief Executive Officer | 57 | 03/08/2018 |
Raylen Tamayo
DFI | Director of Finance/CFO | - | 04/05/2026 |
Mahmoud Aziz
PSD | President | - | 21/05/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Sina Pirooz
BRD | Director/Board Member | 57 | 03/08/2018 |
Jamie Lewin
BRD | Director/Board Member | 76 | 11/03/2019 |
Kevin Bottomley
BRD | Director/Board Member | 48 | 05/09/2019 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 09/09/25 | Option | Chairman | 1,000,000 | 1.6885% | ||
| 09/09/25 | Option | Chairman | 1,000,000 | 1.6885% | ||
| 09/09/25 | Option | Chief Executive Officer | 1,000,000 | 1.6885% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| 0.00% | 0.00% | -50.00% | -62.50% | 644K | ||
| +1.26% | +6.61% | +41.12% | +135.59% | 1,286B | ||
| +0.79% | +3.45% | +46.35% | +93.56% | 688B | ||
| +0.20% | +1.28% | +27.01% | +112.80% | 521B | ||
| -0.44% | +3.69% | +39.60% | +69.51% | 386B | ||
| +0.55% | +0.70% | +59.00% | +44.20% | 364B | ||
| -0.12% | +0.74% | +26.78% | +58.43% | 302B | ||
| +0.37% | +0.37% | +3.62% | +36.44% | 287B | ||
| -0.30% | +1.14% | +38.59% | +74.61% | 252B | ||
| +0.08% | +0.71% | +34.25% | +124.32% | 208B | ||
| Average | +0.24% | +1.87% | +26.63% | +68.69% | 429B | |
| Weighted average by Cap. | +0.54% | +3.26% | +37.63% | +96.23% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 0 0 0 0 0 0.27 0 0.03 0.01 0.14 0.01 0.01 0.45 | - |
| Net income | -73.2K -51.36K -46.54K -43.05K -38.84K -4.84M -75.78K -517K -205K -2.59M -193K -189K -8.21M | -335K -235K -213K -197K -178K -22.17M -347K -2.37M -939K -11.84M -882K -864K -37.59M |
| Net Debt | 804K 564K 511K 473K 427K 53.2M 833K 5.68M 2.25M 28.42M 2.12M 2.07M 90.22M | 999K 701K 635K 588K 530K 66.11M 1.03M 7.06M 2.8M 35.32M 2.63M 2.58M 112M |
Employees
4,000
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|
- Stock Market
- Stocks
- GENX Stock
Select your edition
All financial news and data tailored to specific country editions
















